Share on StockTwits

Charles River Laboratories (NYSE:CRL) Director George Massaro unloaded 10,440 shares of the company’s stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $60.00, for a total value of $626,400.00. Following the completion of the transaction, the director now directly owns 16,510 shares in the company, valued at approximately $990,600. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Charles River Laboratories in a research note on Wednesday, August 13th. They now have a $59.00 price target on the stock, up previously from $58.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Finally, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Charles River Laboratories presently has an average rating of “Hold” and a consensus price target of $58.00.

Shares of Charles River Laboratories (NYSE:CRL) traded down 1.06% during mid-day trading on Wednesday, hitting $59.81. 219,426 shares of the company’s stock traded hands. Charles River Laboratories has a 52 week low of $44.12 and a 52 week high of $62.50. The stock has a 50-day moving average of $55.5 and a 200-day moving average of $56.16. The company has a market cap of $2.792 billion and a price-to-earnings ratio of 24.72.

Charles River Laboratories (NYSE:CRL) last released its earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. Analysts expect that Charles River Laboratories will post $3.33 EPS for the current fiscal year.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.